Alnylam to Webcast Conference Call Discussing Fourth Quarter and 2012 Financial Results

  Alnylam to Webcast Conference Call Discussing Fourth Quarter and 2012
  Financial Results

Business Wire

CAMBRIDGE, Mass. -- January 31, 2013

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics
company, today announced that it will report financial results for the fourth
quarter and year ending December 31, 2012, on Thursday, February 7, 2013,
after the U.S. financial markets close.

Management will provide an update on the company, discuss fourth quarter and
year-end 2012 results, and discuss expectations for the future via conference
call on Thursday, February 7, 2013 at 4:30 p.m. ET. To access the call, please
dial 877-312-7507(domestic) or 631-813-4828(international) five minutes
prior to the start time and refer to conference ID 91074947. A replay of the
call will be available beginning at 7:30 p.m. ET on February 7, 2013. To
access the replay, please dial 855-859-2056(domestic) or
404-537-3406(international) and refer to conference ID 91074947.

A live audio webcast of the call will also be available on the News &
Investors section of the company’s website, An archived
webcast will be available on the Alnylam website approximately two hours after
the event.

About Alnylam Pharmaceuticals

Alnylam is a biopharmaceutical company developing novel therapeutics based on
RNA interference, or RNAi. The company is leading the translation of RNAi as a
new class of innovative medicines with a core focus on RNAi therapeutics for
the treatment of genetically defined diseases, including ALN-TTR for the
treatment of transthyretin-mediated amyloidosis (ATTR), ALN-AT3 for the
treatment of hemophilia and rare bleeding disorders (RBD), ALN-AS1 for the
treatment of acute intermittent porphyria, ALN-PCS for the treatment of
hypercholesterolemia, and ALN-TMP for the treatment of hemoglobinopathies. As
part of its “Alnylam 5x15^TM” strategy, the company expects to have five RNAi
therapeutic products for genetically defined diseases in clinical development,
including programs in advanced stages, on its own or with a partner by the end
of 2015. Alnylam has additional partnered programs in clinical or development
stages, including ALN-RSV01 for the treatment of respiratory syncytial virus
(RSV) infection and ALN-VSP for the treatment of liver cancers. The company’s
leadership position on RNAi therapeutics and intellectual property have
enabled it to form major alliances with leading companies including Merck,
Medtronic, Novartis, Biogen Idec, Roche, Takeda, Kyowa Hakko Kirin, Cubist,
Ascletis, Monsanto, and Genzyme. In addition, Alnylam holds a significant
equity position in Regulus Therapeutics Inc., a company focused on discovery,
development, and commercialization of microRNA therapeutics. Alnylam has also
formed Alnylam Biotherapeutics, a division of the company focused on the
development of RNAi technologies for applications in biologics manufacturing,
including recombinant proteins and monoclonal antibodies. Alnylam’s VaxiRNA™
platform applies RNAi technology to improve the manufacturing processes for
vaccines; GlaxoSmithKline is a collaborator in this effort. Alnylam scientists
and collaborators have published their research on RNAi therapeutics in over
100 peer-reviewed papers, including many in the world’s top scientific
journals such as Nature, Nature Medicine, Nature Biotechnology, and Cell.
Founded in 2002, Alnylam maintains headquarters in Cambridge, Massachusetts.
For more information, please visit


Alnylam Pharmaceuticals, Inc.
Cynthia Clayton, 617-551-8207
Vice President, Investor Relations and
Corporate Communications
Amanda Sellers (Media), 202-955-6222 x2597
Press spacebar to pause and continue. Press esc to stop.